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Selection for Focal Therapy: Is It Too Early to Judge?Luke Dixon, Matthew Brown, Benjamin Challacombe *
Guy’s and St. Thomas’ NHS Foundation Trust, Urology, Guy’s Hospital, London, UKThe advent of novel focal therapies theoretically opens up
new treatment avenues for patients with localised prostate
cancer (PCa). Presently, management is dichotomised
between active surveillance and radical, whole-gland
therapy, such as prostatectomy and radiotherapy. While
the former burdens patients with the detrimental diagnosis
of cancer without the reassurance of treatment, the latter is
too often associated with long-term incontinence and/or
impotence [1]. The ultimate aim in PCa treatment is
effective cure with minimal morbidity and maintenance
of quality of life. Through targeted treatment and resultant
tissue preservation, focal therapy has been hypothesised to
achieve this difficult goal in certain patients. However, the
interminable challenge of patient selection remains.
In this month’s issue of European Urology, Singh and
colleagues report an interesting and important study that
retrospectively looked at all patients who had undergone
transperineal template prostate-mapping biopsies over a
4-yr period [2]. Their creditable aim was to estimate the
proportion of patients with PCa who are appropriate for
focal therapy. Their optimistic conclusion was that 92% of
239 patients (220 men) with PCa were potentially suitable
for focal treatments.
The presence of substantial selection bias in a popula-
tion-based study must, however, be acknowledged, with
the authors only analysing men who had been referred to
their tertiary centre with a special interest in focal therapy.
Furthermore, and crucially, how do we define suitability for
what are currently evolving and experimental treatments?
Singh et al. [2] used broad criteria for suitability, requiring
the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/
bifocal with at least one neurovascular bundle avoided, or
(4) bilateral/multifocal with one dominant index lesion and
secondary lesions with Gleason 3 + 3 and cancer coreDOI of original article: http://dx.doi.org/10.1016/j.eururo.2013.09.045.
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criteria, the greater the proportion of patients deemed
suitable. The crux, however, is that success in these groups
is presently uncertain and hypothetical. Moreover, these
criteria neglect an integral factor in treatment decision:
individual patient health and life expectancy [3].
The core tenet of focal therapy is that the targeted
removal of detectable local disease results in oncologic
control. The secondary assumption is that any undetected
secondary tumours will remain inconsequential. Multi-
focality is highly prevalent (up to 87% in radical prostatec-
tomy series [4]) and many urologists would question the
use of focal therapy where multifocal, intermediate- to
high-risk disease has been detected. Singh’s group and
others rely on the index theory to advocate focal therapy in
these groups [2]. This is the belief that a dominant, index
lesion drives malignant and metastatic potential and that
eradication of this results in effective treatment [5]. This is
supported by the idea of the monoclonal origin of prostatic
metastases [6]. Although intuitive, this remains a theoreti-
cal and as-yet unproven concept that requires long-term
outcome data. Therefore, it is perhaps too early to surmise
that all of thesemen identified by Singh et al. are suitable for
focal therapy [2]. Furthermore, pending robust validation, it
is difficult to counsel patients regarding the effectiveness of
focal treatment.
The success of focal therapy also depends on the
accuracy of the diagnostic technique used and the subse-
quent ability to precisely ablate the identified targets.
Investigative methods have improved in tandem with
evolving focal therapies [7,8], but there is still no ideal tool
for diagnosing and localising PCa. Multiparametric mag-
netic resonance imaging has been demonstrated to
accurately identify PCa foci when compared againstogy, 1st ﬂoor Thomas Guy House, Guy’s Hospital, London, SE1 9RT, UK.
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tainties remain about consistent analysis, and invariably
biopsy is needed for definitive pathologic diagnosis. Singh’s
group reasonably used transperineal template biopsy in
their study, but, unfortunately, even extended biopsy is not
infallible [2]. In a large series of 414 men, a noteworthy
25.6%were upgraded in Gleason gradewhen correlating the
transperineal biopsy with the final radical prostatectomy
specimen [8]. The implication, therefore, is that many men
may be incorrectly allocated to focal rather than radical
treatments. Notably, biopsy is also inherently invasive and
not withoutmorbidity. Singh’s group, for example, reported
haematuria in 2% and urinary retention in 7% of 291 men
biopsied [2]. Arguably, these complications partly under-
mine the supposed low side-effect advantage of focal
therapy. This is compounded by difficulties in monitoring
for recurrence after focal treatment; with imaging and
prostate-specific antigen levels typically difficult to analyse,
additional biopsies are often necessary. The arrival of
focused treatments only emphasises the need for a gold
standard and safe test for PCa.
The potential urinary and sexual dysfunction that can
arise from radical prostate treatment weighs heavily on
patient and physician decision making [1]. This need for
acceptable morbidity is key to the interest in focal therapy.
Early findings are promising; however, side effects such as
urinary retention, dysuria, urinary tract infection, urethral
strictures, and, rarely, rectal fistulas have been reported [9].
Erectile function is also not assured, with a series (n = 70)
reporting impotence in 14% of patients after cryotherapy
[10]. Nonetheless, morbidity rates associated with focal
therapy are better than those reported for radical treat-
ments, and functional outcomes are likely to improve with
experience. An understanding of prostatic neuroanatomy is
specifically needed to limit erectile dysfunction. Tradition-
ally, preservation of a single neurovascular bundle was
thought to confer potency and it is this doctrine that these
authors used to guide their selection criteria [2]. This is
perhaps too reductionist, with recent dissection studies
demonstrating a more complex periprostatic neural net-
work [3,11]. The presence of pro-erectile fibres at the
prostatic apex and anterolaterally is of particular interest
and should perhaps guide future selection criteria [11].
Another issue in focal therapy selection is that patients with
low-volume disease may, in actuality, still be better suited
to side effect-free, active surveillance.
Focal therapy’s position, as a low-morbidity bridge
between the gulf of surveillance and radical treatment ishighly appealing. Although Singh et al. further our
understanding of focal therapy selection, it is too early to
judge how many patients would benefit. Clearly, before we
can identify the proportion of men best suited, we need
validated, evidence-based eligibility criteria. Unnecessary
treatment of insignificant disease and, in turn, under-
treatment of serious disease must be avoided. Consequent-
ly, patient selection for focal modalities presents several
hurdles that only anticipated, long-term outcome studies
can traverse.
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